Liver Disease Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Liver Disease Diagnostics Market is Segmented by Diagnosis Technique (Liver Biopsy, Imaging Tests, Liver Function Tests, and Endoscopy), End User (Hospitals, Laboratories, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Liver Disease Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Liver Disease Diagnostics Market Size

Liver Disease Diagnostics Market
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 5.80 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Global Liver Disease Diagnostics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Liver Disease Diagnostics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Liver Disease Diagnostics Market Analysis

The Global Liver Disease Diagnostics Market is expected to register a CAGR of 5.8% during the forecast period.

COVID-19 had a significant impact on the diagnosis and treatment of diseases other than COVID-19 as all the resources were diverted for the COVID-19 patients and also, due to lockdown restrictions and high chances of contracting infection, the footfall in the hospitals and clinics reduced for diseases other than COVID-19 which was expected to have a significant impact on the studied market. However, it was reported that COVID-19 may have a severe impact on people with liver diseases which might have a positive impact on the liver disease diagnostics market. For instance, according to a research study published in May 2021, titled 'Impact of COVID-19 in Liver Disease Progression', the risk of severe COVID-19 was significantly associated with alcoholic liver damage and alcoholic liver cirrhosis, and also, cirrhosis is associated with immune dysfunction, which is related to a bad COVID-19 prognosis. Hence, COVID-19 is anticipated to have an impact on the liver disease diagnostics market.

The major factors that are expected to fuel growth in the liver disease diagnostics market are the increasing consumption of the alcohol and high prevalence of liver diseases around the world. For instance, according to the research study published in June 2021, titled 'Global Epidemiology of Chronic Liver Disease', chronic liver disease (CLD) is one of the leading causes of mortality and morbidity around the world and affects about 1.5 billion people across the world. Further, as per the same source, the most common causes of prevalent disease are non-alcoholic fatty liver disease (NAFLD) (59%), followed by hepatitis B (29%), hepatitis C (9%), and alcoholic liver disease (ALD) (2%). Similarly, according to a research study published in September 2021, titled 'Global Prevalence of Hepatitis B Virus Serological Markers Among Healthcare Workers: A Systematic Review and Meta-Analysis', hepatitis is a global public health issue, and the hepatitis B virus (HBV) infection affects around 2 billion individuals and results in 1 million fatalities each year. Also, as per the same source, healthcare workers (HCWs) are at high risk for HBV because of the occupational risk to patient blood. Hence, due to the high burden of liver diseases, the demand for liver disease diagnostics products is expected to increase which is anticipated to drive growth in the studied market.

In addition, the increasing consumption of alcohol and an associated risk factor for liver disease like obesity is further expected to have a positive impact on the market as these factors are expected to boost the demand for liver disease diagnostics products. For instance, according to a research study published in December 2021, titled 'Effect of Increased Alcohol Consumption During COVID-19 Pandemic on Alcohol-Associated Liver Disease: A Modeling Study', during the COVID-19 pandemic, a temporary rise in alcohol intake can significantly raise long-term ALD-related morbidity and mortality, and it was observed that the alcohol consumption increases up to 25% in the United States. Also, as per the same source, this increase in consumption can lead to 8,000 additional deaths from alcohol-related liver disease, 18,700 cases of liver failure, and 1,000 cases of liver cancer by 2040, which is expected to increase the demand for effective and advanced diagnostic tools so that appropriate medical attention can be provided to the patient. Therefore, due to the above-mentioned factors, the liver disease diagnostics market is expected to grow over the forecast period. However, high costs associated with liver disease tests are expected to restrain the growth of the studied market over the forecast period.

Liver Disease Diagnostics Industry Overview

The liver disease diagnostics market is fragmented in nature due to the presence of several companies operating globally as well as regionally and thus, it is moderately competitive. SOme of the key companies operating in the industry are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Randox Laboratories Ltd, Boston Scientific Corporation, Laboratory Corporation of America Holdings, Siemens Healthcare GmbH, BioMerieux SA, Quest Diagnostics Incorporated, Biosino Bio-Technology and Science Inc, and Echosens.

Liver Disease Diagnostics Market Leaders

  1. F. Hoffmann-La Roche Ltd

  2. Echosens

  3. Siemens Healthcare GmbH

  4. Boston Scientific Corporation

  5. Thermo Fisher Scientific Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Picture1.png
Need More Details on Market Players and Competiters?
Download PDF

Liver Disease Diagnostics Market News

  • In March 2022, Echosens launched an affordable, cost-effective tool for screening liver health, FibroScan GO in the United Kingdom.
  • In January 2022, Siemens Healthineers launched Enhanced Liver Fibrosis (ELF) Test in the United States, the first and only prognostic blood test granted De Novo marketing authorization to assess disease progression in non-alcoholic steatohepatitis (NASH) patients.

Liver Disease Diagnostics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Alcohol Consumption
    • 4.2.2 Increase in Prevalence of Liver Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Diagnostic Test
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Diagnosis Technique
    • 5.1.1 Liver Biopsy
    • 5.1.2 Imaging Tests
    • 5.1.3 Liver Function Tests
    • 5.1.4 Endoscopy
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Laboratories
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott
    • 6.1.2 F. Hoffmann-La Roche Ltd.
    • 6.1.3 Thermo Fisher Scientific Inc.
    • 6.1.4 Randox Laboratories Ltd.
    • 6.1.5 Boston Scientific Corporation
    • 6.1.6 Laboratory Corporation of America Holdings
    • 6.1.7 Siemens Healthcare GmbH
    • 6.1.8 BioMerieux SA
    • 6.1.9 Quest Diagnostics Incorporated
    • 6.1.10 Biosino Bio-Technology and Science Inc
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Liver Disease Diagnostics Industry Segmentation

As per the scope of the report, diagnostic procedures for liver disease aid in determining the liver's condition. When liver cells die, their chemical constituents are discharged into the bloodstream, which aids in the detection of liver illness through liver function tests. The liver disease diagnostics market is segmented by diagnosis technique (liver biopsy, imaging tests, liver function tests, and endoscopy), end user (hospitals, laboratories, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Diagnosis Technique Liver Biopsy
Imaging Tests
Liver Function Tests
Endoscopy
By End User Hospitals
Laboratories
Other End Users
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Liver Disease Diagnostics Market Research FAQs

What is the current Global Liver Disease Diagnostics Market size?

The Global Liver Disease Diagnostics Market is projected to register a CAGR of 5.8% during the forecast period (2025-2030)

Who are the key players in Global Liver Disease Diagnostics Market?

F. Hoffmann-La Roche Ltd, Echosens, Siemens Healthcare GmbH, Boston Scientific Corporation and Thermo Fisher Scientific Inc. are the major companies operating in the Global Liver Disease Diagnostics Market.

Which is the fastest growing region in Global Liver Disease Diagnostics Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Liver Disease Diagnostics Market?

In 2025, the North America accounts for the largest market share in Global Liver Disease Diagnostics Market.

What years does this Global Liver Disease Diagnostics Market cover?

The report covers the Global Liver Disease Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Liver Disease Diagnostics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Global Liver Disease Diagnostics Industry Report

Statistics for the 2025 Global Liver Disease Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Liver Disease Diagnostics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.